In our previous study in breast cancer [16], the favourable prognostic impact of RBM3 was assessed by IHC in two independent patients cohorts using a polyclonal, monospecific antibody, initially developed within the HPA programme [23,36]. The gene discussed is RBM3; the disease is breast cancer.